ARTICLE | Company News
Stanford University, Cortice Biosciences deal
September 22, 2014 7:00 AM UTC
Stanford granted Cortice exclusive commercialization rights to a portfolio of small molecules to treat diseases associated with cognitive impairment. The lead candidate, CRT 001, is a selective parti...